• Aria

  Participated · Debt Financing · Jul 2026

  Aria offers an embedded invoice financing platform that buys suppliers’ invoices and embeds financing via a single API into marketplaces, ERP systems, and vertical SaaS, enabling suppliers to be paid immediately while buyers retain usual payment terms. The platform handles identity checks, credit assessments, collections, insurance and payments, and adapts to local rules, currencies and payment methods across Europe. Since launching in 2020 it has financed over €1.5 billion in invoices and reports a default rate below 0.1%. Aria financed 1.7 million invoice advances in 2025 and over 1.1 million more so far in 2026, and currently powers more than 70 European B2B marketplaces and freelance platforms, including Malt and Job&Talent. The company plans to expand its presence in sectors with acute late-payment problems such as transportation, manufacturing and construction. Its positioning emphasizes embedding infrastructure (one API, no redirects or separate signups) to increase predictability of cash flow for SMB suppliers.

• UroMems

  Participated · Series C · Jun 2024

  UroMems develops implantable mechatronics to treat stress urinary incontinence, centered on its UroActive smart automated artificial urinary sphincter. UroActive is an active implantable electronic AUS powered by a MyoElectroMechanical System (MEMS) designed to respond to patient activity without manual adjustments. The technology platform is protected by more than 200 granted patents and the company reports having surpassed key R&D and clinical milestones. UroMems is currently running the SOPHIA2 pivotal clinical trial in 21 centers across the U.S. and France as it prepares for regulatory submissions and commercialization. UroActive has not received FDA marketing authorization and is not available for sale in the U.S. or EU. The company has signaled plans to use recent financing to complete pivotal trials and advance toward regulatory approval and launch preparation.

• Germitec SAS

  Participated · Equity · May 2022

  Germitec develops and manufactures UV-C high-level disinfection systems aimed primarily at disinfecting ultrasound probes used in fertility (IVF), gynecology, cardiology and ENT. Its products are available in 40 countries and protect approximately 2.2 million patients worldwide each year. The company received an FDA De Novo granted in August 2024 and cites a U.S. market opportunity of 60,000 units. Germitec says it is positioned to double its revenue every year with profitability on the horizon. Proceeds from the recent financing will be used to scale U.S. operations, accelerate commercial adoption and invest in R&D to expand its product portfolio. Combined with prior financing from the European Investment Bank in 2023, the company expects sustained growth over the next two years. GERMITEC designs and commercializes automated UV‑C high‑level disinfection (HLD) systems for external, vaginal, rectal and transesophageal ultrasound probes, including products Hypernova Chronos, Antigermix AE1 and the PROUV traceability system. The company positions its chemical‑free devices as faster, simpler and cleaner replacements for wipes, soaking and hydrogen peroxide workflows and notes approvals in over 35 countries. GERMITEC says its UV‑C HLD address Healthcare‑Acquired Infections and aims to make UV‑C HLD a standard of care; its market opportunity is cited at about €245M. The company has 15 years of product development experience and won the 2020 Prix Galien for Best Medical Device. With the new capital and management team, GERMITEC plans European and international commercial expansion and is preparing a U.S. go‑to‑market strategy following planned FDA clearance. The financing and leadership changes are framed as steps to transform GERMITEC into a high‑growth commercial company and to continue product innovation and operational structuring.

• Adwanted Group

  Led · Equity · May 2021

  Adwanted Group is an independent and international portfolio of cross-channel media and advertising technology platforms and advertising sales firms that operates the Adwanted platform and subsidiaries including Carthage, Affinity Media, Audience Media, Media Opportunities and Access Outdoor. Founded in 2012 by CEO Emmanuel Debuyck, the company structures its offering around three categories: Buy Side (DSP, media planning, events), Sell Side (SSP/booking software, on-air conductor, events) and Data (audience data and analysis tools). It operates in Europe, Asia and North America and recently acquired UK counterpart Mediatel to expand into the United Kingdom and export its technology and data solutions there. Thanks to the Mediatel acquisition, Adwanted Group now has a turnover of €20 million and a solid base in France, the United States and the United Kingdom. The group intends to use new funding to continue expanding operations and its business reach and to consolidate its positions in those regions and across Europe through additional acquisitions. Adwanted is a Lille-based startup that operates a marketplace for buying and selling multi-media advertising space. The company runs a proprietary technology platform that supports its marketplace. It has raised €2.6 million in new funding. The financing will enable continued investment in its technology platform and support international development. Adwanted plans to intensify its presence in the US market and grow its subsidiaries in London and Madrid. Investors in the round were private backers based in New York and London.

• keepMED

  Participated · Series C · Sep 2020

  keepMed designs and develops keePAP, a hoseless, wearable, responsive and personalized positive airway pressure device that delivers PAP intermittently with minimal airflow by mobilizing the user’s respiratory system. Unlike traditional PAP devices that deliver continuous high-flow air, keePAP provides on-demand pressure only as needed. The company completed CE certification and finished a first-in-human study at the end of 2019. keepMed plans to use proceeds from its recent financing to advance clinical development toward FDA clearance and a market launch in the USA and Europe. The device targets treatment of Obstructive Sleep Apnea, a widespread disorder associated with increased cardiovascular and metabolic risk and major quality-of-life impacts. keepMed is based in Israel and emphasizes a minimally invasive, patient-friendly alternative to conventional PAP therapy. Ninox Medical, founded in 2012 and based in Lyon, France, develops and commercializes a device to treat obstructive sleep apnea. Its core product, the KeePAP™ device, is a small wearable Automatic Positive Airway Pressure (APAP) system that does not require the air blower or mask used in existing solutions. The company is led by CEO Alex Rapoport. Ninox recently completed a $10M Series B financing to support its next growth phase. The funds are earmarked to scale operations, further develop KeePAP™ to obtain CE Mark and 510(k) approvals, reinforce management and technical teams, and build infrastructure for larger clinical trials and commercialization.

No current team members are available.